Over the years, early diagnosis of myocardial ischemia has ranged from 0-to-3-h protocols to abbreviated guidelines with point-of-care cardiac marker dosing. However, specific devices for this have not yet been validated. The Sengupta P. et al. research group evaluated the feasibility of using an infrared measuring device—placed on the wrist of patients—compared with blood sampling…
ACC 2023 | Subanalysis of the REVIVED-BICS Study2
This study demonstrated that coronary angioplasty does not entail any benefit in chronic stable angina over optimal medical therapy in those with impaired ventricular function (EF >35%) with extensive coronary artery disease and viable myocardium. Dr. Divaka Perera performed a subanalysis of said study. At the time of the study, the amount of viability and…
ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease
Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab on coronary plaque in patients with stable coronary artery disease. The study included 137 patients who underwent coronary angioplasty to the culprit vessel and endovascular imaging (OCT, NIRS/IVUS) to non-obstructive lesions (30%-50%). If their plaque was lipid-rich (defined…
ACC 2023 | Complete Revascularization Strategies in patients with ACS and Multivessel Disease
In patients with acute coronary syndrome (ACS) and multivessel disease, complete revascularization is associated with better clinical outcomes. However, for non-culprit vessel revascularization the strategy remains unclear. The aim of this multicenter, open label, randomized, non-inferiority study, was to determine whether complete revascularization during index procedure is non inferior vs. staged. Primary end point was…